Institutions suddenly entered the market on a run

The market bottomed out in early trading today, and the overall performance was average. There were nearly 60 stocks that rose more than 9%. On the disk, the coal, paper, and liquor sectors ranked among the top gainers, while the environmental protection, power Internet of Things, and e-sports sectors ranked among the top decliners.

Today, there are 3 new ETFs listed, namely CCB CSI Innovative Pharmaceutical Industry ETF, Celestica CSI Full Index Healthcare Equipment and Services ETF, and Boshi Hang Seng Healthcare ETF (QDII). As of the close of trading at noon, they rose 0.36 and 1.17 respectively. % And fell 0.5%. It is worth noting that the number of ETFs tracking the China Securities Innovative Drug Industry Index in the two cities has reached six, and the competition is very fierce.

CCB China Securities Innovative Drug Industry ETF

Chuangxin Pharmaceutical has 305 million fund shares in this IPO. As of March 22, 2021, stocks accounted for 63.82% of the fund’s total assets in the fund’s asset portfolio; bank deposits and settlement reserves accounted for the total fund’s total assets. The ratio of assets is 36.14%. Among the top ten heavyweight stocks, WuXi AppTec and Hengrui Pharmaceuticals accounted for more than 6% of their net worth; judging from the gains and losses in the past three months, only four of the top ten heavyweight stocks rose, Zhifei Biotech, Wo Sen Biotech performed best, rising by 20.31% and 14.29%, respectively, while Fosun Pharma and Kangtai Biotech fell by more than 20%.

The tracking subject of Innovative Medicine is the China Securities Innovative Medicine Industry Index (index code: 931152). The index is based on December 31, 2014, and is based on 1,000 points. As of March 26, the latest closing price was 3158.61 points. , The index has fallen by 3.01% in the past three months.

Trends in the China Securities Innovative Drug Industry Index in the past three months

Public information shows that the China Securities Innovative Drug Industry Index selects listed companies whose main business involves the research and development of innovative drugs as candidate samples, and selects no more than 50 most representative companies as sample stocks in order of market value, reflecting the performance of listed companies in the innovative drug industry The overall performance provides investors with new investment targets. Among the top ten heavyweight stocks, WuXi AppTec’s weight exceeds 11%, and Hengrui Pharmaceuticals and Changchun Hi-tech both exceed 9%. It is worth noting that the number of ETFs tracking the China Securities Innovative Drug Industry Index in the two cities has reached six. The competition is very fierce. The largest is the innovative drug (159992), with a share of 2.897 billion copies and a scale of 3.912 billion yuan. The year-to-date share has decreased by 641 million copies. 6 ETFs that track the China Securities Innovative Drug Industry Index Spark Global Limited.

Celestica CSI refers to all healthcare equipment and services ETF

(Trading code: 159873; on-site abbreviation: medical equipment)

Medical equipment’s fund shares in this IPO transaction are 232 million. As of March 22, 2021, stocks accounted for 4.87% of the fund’s total assets in the fund’s asset portfolio; bank deposits and settlement reserves accounted for the total of the fund’s total assets The ratio is 95.07%. Among the top ten heavyweight stocks, Mindray Medical and Tigermed Pharmaceuticals accounted for more than 0.5% of their net worth; judging from the gains and losses in the past three months, half of the top ten heavyweight stocks rose, of which Meinian Health surged 48.15%, and Tigermed and Aier Ophthalmology fell more than 13%.

 

©Spark Global Limited Financial information & The content of the website comes from the Internet, and any infringement links will be deleted.